Scholar Rock Holding Corp
$ 49.55
0.06%
14 Apr - close price
- Market Cap 5,689,011,000 USD
- Current Price $ 49.55
- High / Low $ 50.34 / 48.89
- Stock P/E N/A
- Book Value 2.26
- EPS -3.29
- Next Earning Report 2026-05-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.55 %
- ROE -1.23 %
- 52 Week High 51.62
- 52 Week Low 27.07
About
Scholar Rock Holding Corporation, a clinical-phase biopharmaceutical company, is focused on the discovery and development of drugs for the treatment of serious diseases in which protein growth factor signaling plays a critical role. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$57.43
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-10 | 2025-11-14 | 2025-08-06 | 2025-05-05 | 2025-03-17 | 2024-11-12 | 2024-08-08 | 2024-05-07 | 2024-03-19 | 2023-11-07 | 2023-08-09 | 2023-05-09 |
| Reported EPS | -0.88 | -0.9 | -0.98 | -0.67 | -0.61 | -0.6644 | -0.6 | -0.59 | -0.5 | -0.53 | -0.47 | -0.49 |
| Estimated EPS | -0.8983 | -0.84 | -0.66 | -0.7076 | -0.6288 | -0.6 | -0.61 | -0.51 | -0.49 | -0.52 | -0.56 | -0.58 |
| Surprise | 0.0183 | -0.06 | -0.32 | 0.0376 | 0.0188 | -0.0644 | 0.01 | -0.08 | -0.01 | -0.01 | 0.09 | 0.09 |
| Surprise Percentage | 2.0372% | -7.1429% | -48.4848% | 5.3137% | 2.9898% | -10.7333% | 1.6393% | -15.6863% | -2.0408% | -1.9231% | 16.0714% | 15.5172% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-13 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.82 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SRRK
2026-04-08 14:10:55
Scholar Rock Holding Corp's stock has reached a 52-week high of $51.50, reflecting a 104% one-year return and a 29% gain in the past six months, driven by investor confidence and advancing therapies. Despite trading above its Fair Value according to InvestingPro, the company has positively advanced its Biologics License Application for apitegromab and received increased price targets from Jefferies and BofA Securities. This positive outlook is further supported by the discontinuation of a competing drug's development.
2026-04-08 07:10:59
Scholar Rock (SRRK) has resubmitted its Biologics License Application for apitegromab to the FDA, following facility remediation and the addition of a second fill-finish site. The company's shares have seen significant returns, and its valuation narrative suggests it is 11.4% undervalued with a fair value of $55.07, based on future revenue projections despite current lack of revenue. However, this valuation depends on timely regulatory clearance and controlled launch spending.
2026-04-06 20:39:29
Mohammed Qatanani, an insider at Scholar Rock Holding Corp (NASDAQ: SRRK), filed a Form 144 to sell 23,408 shares of common stock on April 6, 2026, through a stock option exercise for cash. The filing also revealed three prior sales within the last three months, totaling 36,494 shares. These sales include 13,112 shares on January 14, 2026, 14,898 shares on January 22, 2026, and 8,484 shares on February 23, 2026.
2026-04-05 20:39:59
The article provides news and information about Scholar Rock Holding Corp (NASDAQ: SRRK), including its current stock price and recent performance. It lists various sections available on ChartMill.com for in-depth analysis of the company, such as stock charts, technical analysis, fundamentals, and earnings. The primary focus is on providing all press releases related to SRRK.
2026-04-02 06:39:29
This article compiles a list of 10 analyst ratings changes for various companies, including upgrades, downgrades, and price target adjustments. Notable shifts include Piper Sandler upgrading nCino, HC Wainwright & Co. downgrading Apellis Pharmaceuticals, and Wedbush raising the price target for Scholar Rock Holding Corp. The article provides insight into how Wall Street analysts view these stocks.
2026-04-02 05:39:55
SCHOLAR ROCK HOLDING CORP (NASDAQ:SRRK) has a strong technical rating of 10 out of 10, showing consistent positive performance in both short and long term timeframes, outperforming 89% of all stocks and 70% of its industry peers. While its technical rating is excellent, its setup rating is 3 due to recent price volatility, suggesting a wait for consolidation before entry. The stock is currently trading near its 52-week high, with increasing volume, and displays positive trends across various technical indicators despite some indicating it might be overbought or experiencing high volatility.
